Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis.
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS] (RECYCLINE)
Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis.
Multiple sclerosis disease-modifying therapy prescribing patterns in ontario.
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Ampyra 10mg beats 5mg, but weak overall results net neutral for ACOR
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Tractography Analysis of 5 White Matter Bundles and Their Clinical and Cognitive Correlates in Early-Course Schizophrenia.
3H-1,2-dithiole-3-thione as a novel therapeutic agent for the treatment of experimental autoimmune encephalomyelitis.
The effect of supported standing in adults with upper motor neurone disorders: a systematic review.
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Rehabilitation in transverse myelitis.
Fatal Neuroinflammation in a Case of Multiple Sclerosis with Anti-Natalizumab Antibodies.
Elevated Expression of the Cerebrospinal Fluid Disease Markers Chromogranin A and Clusterin in Astrocytes of Multiple Sclerosis White Matter Lesions.
[Immunodepressive therapy in neurology].
Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Substance Name: Dronabinol
Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis.
Sex ratio of multiple sclerosis in Canada: a longitudinal study.
The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.

Pages